Orexigen Offers Robust Contrave Risk Plan To Monitor For Safety Concerns

Orexigen brought a robust risk management plan and a post-market surveillance program to the Dec. 7 advisory committee review of its weight-loss drug Contrave, forestalling some of the questions that arose during assessments of other compounds seeking to enter the obesity space.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet